AU1301697A - Tyrosin-derivate as alpha-v-integrin inhibitors - Google Patents

Tyrosin-derivate as alpha-v-integrin inhibitors

Info

Publication number
AU1301697A
AU1301697A AU13016/97A AU1301697A AU1301697A AU 1301697 A AU1301697 A AU 1301697A AU 13016/97 A AU13016/97 A AU 13016/97A AU 1301697 A AU1301697 A AU 1301697A AU 1301697 A AU1301697 A AU 1301697A
Authority
AU
Australia
Prior art keywords
tyrosin
derivate
alpha
integrin inhibitors
integrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU13016/97A
Inventor
Beate Diefenbach
Claus Fittschen
Joachim Gante
Simon Goodman
Friedrich Rippmann
Matthias Wiesner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU1301697A publication Critical patent/AU1301697A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00—Compounds containing azido groups
    • C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/04—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/08—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/14—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
AU13016/97A 1995-12-23 1996-12-16 Tyrosin-derivate as alpha-v-integrin inhibitors Abandoned AU1301697A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19548709A DE19548709A1 (en) 1995-12-23 1995-12-23 Tyrosine derivatives
DE19548709 1995-12-23
PCT/EP1996/005646 WO1997023451A1 (en) 1995-12-23 1996-12-16 Tyrosin-derivate as alpha-v-integrin inhibitors

Publications (1)

Publication Number Publication Date
AU1301697A true AU1301697A (en) 1997-07-17

Family

ID=7781401

Family Applications (1)

Application Number Title Priority Date Filing Date
AU13016/97A Abandoned AU1301697A (en) 1995-12-23 1996-12-16 Tyrosin-derivate as alpha-v-integrin inhibitors

Country Status (14)

Country Link
EP (1) EP0879227A1 (en)
JP (1) JP2000502664A (en)
KR (1) KR19990076676A (en)
AU (1) AU1301697A (en)
BR (1) BR9612201A (en)
CA (1) CA2241149A1 (en)
CZ (1) CZ195198A3 (en)
DE (1) DE19548709A1 (en)
HU (1) HUP9903716A2 (en)
NO (1) NO982907L (en)
PL (1) PL327185A1 (en)
SK (1) SK78398A3 (en)
WO (1) WO1997023451A1 (en)
ZA (1) ZA9610725B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU742928B2 (en) * 1997-08-22 2002-01-17 F. Hoffmann-La Roche Ag N-alkanoylphenylalanine derivatives

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19629816A1 (en) 1996-07-24 1998-01-29 Hoechst Ag New cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists
US5900414A (en) * 1996-08-29 1999-05-04 Merck & Co., Inc. Methods for administering integrin receptor antagonists
US6245809B1 (en) 1996-12-09 2001-06-12 Cor Therapeutics Inc. Integrin antagonists
CA2272090A1 (en) * 1996-12-09 1998-06-18 Matthew J. Fisher Integrin antagonists
US6559144B2 (en) 1997-02-13 2003-05-06 Merck Patent Gesellschaft Mit Bicyclic amino acids
DE19705450A1 (en) * 1997-02-13 1998-08-20 Merck Patent Gmbh Bicyclic aromatic amino acids
US6455550B1 (en) 1997-08-22 2002-09-24 Hoffmann-La Roche Inc. N-alkanoylphenylalanine derivatives
PL193283B1 (en) * 1997-08-22 2007-01-31 Hoffmann La Roche Derivatives of n-arylphenylalanine
JP4064059B2 (en) 1998-04-09 2008-03-19 明治製菓株式会社 Aminopiperidine derivatives as integrin αVβ3 antagonists
ATE266400T1 (en) * 1998-07-31 2004-05-15 Lilly Co Eli HETEROCYCLYL SULPHONAMIDE DERIVATIVES
DE19842415A1 (en) * 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmaceutical preparation for treating e.g. tumors, thrombosis or inflammation, contains cyclic pentapeptide integrin inhibitor and chemotherapeutic agent and/or angiogenesis inhibitor
KR20010086112A (en) * 1998-12-16 2001-09-07 빌프리더 하이더 New Biphenyl and Biphenyl-analogous Compounds as Integrin Antagonists
US6677360B2 (en) 1998-12-16 2004-01-13 Bayer Aktiengesellschaft Biphenyl and biphenyl-analogous compounds as integrin antagonists
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
AR035476A1 (en) 1999-01-22 2004-06-02 Elan Pharm Inc HETEROARILO AND HETEROCICLIC COMPOUNDS WITH FUSIONED RING, WHICH INHIBIT THE ADHESION OF LEUKOCYTES THROUGH VLA-4, PHARMACEUTICAL COMPOSITIONS, THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND A BIOLOGICAL METHOD 4
WO2000043369A1 (en) * 1999-01-22 2000-07-27 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
ES2339738T3 (en) * 1999-01-22 2010-05-25 Elan Pharmaceuticals, Inc. DERIVATIVES OF ACILO WHICH TREAT DISORDERS RELATED TO VLA-4.
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6344484B1 (en) 1999-02-12 2002-02-05 3-Dimensional Pharmaceuticals, Inc. Tyrosine alkoxyguanidines as integrin inhibitors
EP1028114A1 (en) * 1999-02-13 2000-08-16 Aventis Pharma Deutschland GmbH Novel guanidine derivatives as inhibitors of cell adhesion
NZ513254A (en) 1999-02-18 2003-10-31 F Thioamide derivatives
WO2000051974A1 (en) 1999-03-01 2000-09-08 Elan Pharmaceuticals, Inc. Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 - receptor antagonists
CZ20013678A3 (en) 1999-04-13 2002-07-17 Basf Aktiengesellschaft Ligands of integrin receptor
EP1209152A4 (en) 1999-08-05 2003-03-12 Meiji Seika Kaisha Omega-amino-alpha-hydroxycarboxylic acid derivatives having integrin alpha v beta 3 antagonism
RU2001114518A (en) 1999-09-29 2003-04-20 Орто-Макнейл Фармасьютикал, Инк. (Us) ISONIPECOTAMIDES FOR TREATMENT OF INTEGRIN-MEDIATED DISORDERS
US6531495B1 (en) 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
WO2001027082A1 (en) * 1999-10-08 2001-04-19 Meiji Seika Kaisha, Ltd. 3-AMINOPIPERIDINE DERIVATIVES AS INTEGRIN αvβ3 ANTAGONISTS
US20020037897A1 (en) * 2000-08-07 2002-03-28 3-Dimensional Pharmaceuticals, Inc. Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists
US6486174B2 (en) 2000-08-07 2002-11-26 3-Dimensional Pharmaceuticals, Inc. Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists
ES2376161T3 (en) 2001-01-29 2012-03-09 Janssen Pharmaceuticals, Inc. SUBSTITUTE INDOLES AND THEIR USE AS AN INTEGRINE ANTAGONISTS.
FR2822827B1 (en) * 2001-03-28 2003-05-16 Sanofi Synthelabo NOVEL N- (ARYLSULFONYL) BETA-AMINOACIDS DERIVATIVES COMPRISING A SUBSTITUTED AMINOMETHYL GROUP, THEIR PREPARATION METHOD AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
DE60208186T2 (en) 2001-04-09 2006-08-24 Ortho-Mcneil Pharmaceutical Research Inc. CHINAZOLIN AND CHINAZOLE-RELATED COMPOUNDS FOR THE TREATMENT OF INTEGRIN-MEDIATED DISEASES
US6872730B2 (en) 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
WO2003008373A1 (en) * 2001-07-19 2003-01-30 Merck Patent Gmbh Tyrosine hydrazides
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
BRPI0616643A2 (en) 2005-09-29 2011-06-28 Elan Pharm Inc carbamate compounds that inhibit vla-4 mediated leukocyte adhesion
CA2624450C (en) 2005-09-29 2014-02-04 Elan Pharmaceuticals, Inc. Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by vla-4
BRPI0708331A2 (en) 2006-02-27 2011-05-24 Elan Pharm Inc pyrimidinyl sulfonamide compounds that inhibit vla-4 mediated leukocyte adhesion
CA2760151A1 (en) 2009-04-27 2010-11-04 Elan Pharmaceuticals, Inc. Pyridinone antagonists of alpha-4 integrins
WO2012103328A1 (en) * 2011-01-26 2012-08-02 The Methodist Hospital Research Institute Labeled, non- peptidic multivalent integrin alpha -v - beta - 3 antagonists, compositions containing them and their use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
IL99537A (en) * 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU742928B2 (en) * 1997-08-22 2002-01-17 F. Hoffmann-La Roche Ag N-alkanoylphenylalanine derivatives
AU742928C (en) * 1997-08-22 2003-02-20 F. Hoffmann-La Roche Ag N-alkanoylphenylalanine derivatives

Also Published As

Publication number Publication date
KR19990076676A (en) 1999-10-15
CA2241149A1 (en) 1997-07-03
PL327185A1 (en) 1998-11-23
CZ195198A3 (en) 1998-11-11
WO1997023451A1 (en) 1997-07-03
BR9612201A (en) 1999-07-13
NO982907D0 (en) 1998-06-22
MX9804971A (en) 1998-09-30
SK78398A3 (en) 1998-11-04
HUP9903716A2 (en) 2000-03-28
DE19548709A1 (en) 1997-07-03
ZA9610725B (en) 1997-06-26
JP2000502664A (en) 2000-03-07
NO982907L (en) 1998-06-22
EP0879227A1 (en) 1998-11-25

Similar Documents

Publication Publication Date Title
AU1301697A (en) Tyrosin-derivate as alpha-v-integrin inhibitors
AU5235796A (en) o-hydroxyphenyl-s-triazines
AU4780896A (en) Core-board
AU6000496A (en) Phenylpyridazinones
AU5896396A (en) Pyridine-microbicides
AU6304196A (en) Substituted cyanophenyluracils
AU1030997A (en) Taphane
AU4996696A (en) 2-benzyl-3-arylbenzothiophenes
AU5147496A (en) Fucopeptides
AU5593896A (en) Benzisothiazolyl-substituted aminomethylchromans
AU5500196A (en) Anti-transpirants
AU4382896A (en) Acetylimidazobenzodiazepines
AU6049796A (en) Lysyloxidase inhibitors
AU6304396A (en) Substituted carbonylaminophenyluracils
AU7038196A (en) 1-azinyl-tetrazolinones
AU5108596A (en) Morphine-3-esters
AU6215196A (en) Piperidinylmethyloxazolidinones
AU5917896A (en) Poly-beta-1-4-N-acetylglucosamine
AU5013796A (en) Wireclamp
AU2812195A (en) Inhibitor
AU5107096A (en) Haemodialyser
AU6860296A (en) Cycloanthelmintic inhibitors
AU8159594A (en) Novel inhibitor
AU4569496A (en) Tetralinyl- and indanyl-ethylamides
AU6840796A (en) Sack-holder

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted